135 related articles for article (PubMed ID: 27903949)
1. Possible Drug-Herb Interaction between Herbal Supplement Containing Horsetail ( Equisetum arvense) and Antiretroviral Drugs.
Cordova E; Morganti L; Rodriguez C
J Int Assoc Provid AIDS Care; 2017; 16(1):11-13. PubMed ID: 27903949
[TBL] [Abstract][Full Text] [Related]
2. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
[TBL] [Abstract][Full Text] [Related]
3. Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy.
Blanco JL; Montaner JS; Marconi VC; Santoro MM; Campos-Loza AE; Shafer RW; Miller MD; Paredes R; Harrigan R; Nguyen ML; Perno CF; Gonzalez-Hernandez LA; Gatell JM
AIDS; 2014 Nov; 28(17):2531-9. PubMed ID: 25574957
[TBL] [Abstract][Full Text] [Related]
4. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
[TBL] [Abstract][Full Text] [Related]
5. Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio.
Martínez E; Ribera E; Clotet B; Estrada V; Sanz J; Berenguer J; Rubio R; Pulido F; Larrousse M; Curran A; Negredo E; Arterburn S; Ferrer P; Álvarez ML
HIV Med; 2015 Jul; 16(6):370-4. PubMed ID: 25496141
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
[TBL] [Abstract][Full Text] [Related]
7. A potential drug-herbal interaction between Ginkgo biloba and efavirenz.
Naccarato M; Yoong D; Gough K
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(2):98-100. PubMed ID: 22323244
[TBL] [Abstract][Full Text] [Related]
8. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T
AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782
[TBL] [Abstract][Full Text] [Related]
9. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine.
DeJesus E; Ruane P; McDonald C; Garcia F; Sharma S; Corales R; Ravishankar J; Khanlou H; Shamblaw D; Ecker J; Ebrahimi R; Flaherty J;
HIV Clin Trials; 2008; 9(2):103-14. PubMed ID: 18474495
[TBL] [Abstract][Full Text] [Related]
10. Equisetum arvense (common horsetail) modulates the function of inflammatory immunocompetent cells.
Gründemann C; Lengen K; Sauer B; Garcia-Käufer M; Zehl M; Huber R
BMC Complement Altern Med; 2014 Aug; 14():283. PubMed ID: 25088216
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial.
Wilkins E; Fisher M; Brogan AJ; Talbird SE; La EM
HIV Med; 2016 Aug; 17(7):505-15. PubMed ID: 26663715
[TBL] [Abstract][Full Text] [Related]
12. Antioxidative and antiproliferative activities of different horsetail (Equisetum arvense L.) extracts.
Cetojević-Simin DD; Canadanović-Brunet JM; Bogdanović GM; Djilas SM; Cetković GS; Tumbas VT; Stojiljković BT
J Med Food; 2010 Apr; 13(2):452-9. PubMed ID: 20170379
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
Gallien S; Flandre P; Nguyen N; De Castro N; Molina JM; Delaugerre C
J Med Virol; 2015 Feb; 87(2):187-91. PubMed ID: 25070158
[TBL] [Abstract][Full Text] [Related]
14. Chemical fingerprinting of Equisetum arvense L. using HPTLC densitometry and HPLC.
Gallo FR; Multari G; Federici E; Palazzino G; Giambenedetti M; Petitto V; Poli F; Nicoletti M
Nat Prod Res; 2011 Aug; 25(13):1261-70. PubMed ID: 21854173
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
Moreno Guillen S; Losa García JE; Berenguer Berenguer J; Martínez Sesmero JM; Cenoz Gomis S; Graefenhain R; Lopez Sanchez-Cambronero D; Parrondo Garcia FJ
Farm Hosp; 2017 Sep; 41(5):601-610. PubMed ID: 28847249
[TBL] [Abstract][Full Text] [Related]
16. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.
Rokx C; Gras L; van de Vijver D; Verbon A; Rijnders B;
HIV Med; 2016 Sep; 17(8):571-80. PubMed ID: 26842457
[TBL] [Abstract][Full Text] [Related]
17. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
Moyle GJ; Stellbrink HJ; Compston J; Orkin C; Arribas JR; Domingo P; Granier C; Pearce H; Sedani S; Gartland M;
Antivir Ther; 2013; 18(7):905-13. PubMed ID: 23899468
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
[TBL] [Abstract][Full Text] [Related]
19. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
[TBL] [Abstract][Full Text] [Related]
20. More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort.
Rokx C; Fibriani A; van de Vijver D; Verbon A; Schutten M; Gras L; Rijnders BJ
J Int AIDS Soc; 2014; 17(4 Suppl 3):19491. PubMed ID: 25394000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]